Cerapedics Inc., a US-based, commercial-stage musculoskeletal company involved in bone repair, announced on Thursday that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for PearlMatrix P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for skeletally mature patients with degenerative disc disease in the lumbar spine.
The NTAP designation provides supplemental reimbursement to hospitals and healthcare facilities that utilise novel technologies that represent significant clinical advances. PearlMatrix was granted NTAP status under CMS' alternative NTAP pathway, which recognises the transformative nature of products that have received US FDA Breakthrough Device designation.
Inclusion in the NTAP program highlights the potential to address a critical need for patients requiring faster fusion products. Cerapedics says that PearlMatrix is the first and only bone growth accelerator proven to substantially increase lumbar fusion speed.
The NTAP program applies to eligible Medicare beneficiaries receiving inpatient care at hospitals paid under the Medicare Inpatient Prospective Payment System (IPPS). For qualifying inpatient cases involving PearlMatrix, NTAP approval allows for up to 65% reimbursement of the additional cost associated with the technology. This approval can help support patient access to innovative medical technologies during the early stages of adoption, and can also influence commercial insurers as they consider recent technology like PearlMatrix.
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
Abbott secures CE Mark for Cologuard Plus in Europe
VibroSense Dynamics secures Thai regulatory approval for VibroSense Meter II
SciBase technology selected as primary endpoint in NIH-led skin exposure study
FDA approves Vantis Vascular's 6F CrossFAST model
TWINBIRD launches portable freezer targeting dry-ice-free research cold chains
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay